Table 1.
Class | Drug | Mechanism of Action | Type of Seizure Targeted | Effects on OS and Inflammation Markers in Epilepsy (Pre- and Clinical Data) | References |
---|---|---|---|---|---|
Classical anti-epileptic | Valproic acid | Blocks voltage-gated ion channels | Focal and generalized | Increased lipid peroxidation | [111] |
Phenytoin | Blocks voltage-gated sodium channels | Tonic-clonic | Reduced antioxidant capacity and glutathione concentration; Increased lipid peroxidation | [112,113] | |
Carbamazepine | Blocks sodium channels | Focal and generalized | Decreased lipid peroxidation; Increased NO release | [114] | |
Barbitures | Potentiates GABA signalling | Generalized | Decreased lipid peroxidation; Reduced levels of antioxidant enzymes | [115] | |
Benzodiazepines | Facilitates GABA binding to GABAA receptors | Status epilepticus | Decreased lipid peroxidation | [116] | |
Cenobamate | Blocks voltage-gated sodium channels. Allosteric agonist of GABA receptors | Uncontrolled focal | Activation of the PI3K/Akt-CREB-BDNF pathway | [117,118] | |
Lamotrigine | Binds to the inactive sodium channel | Focal and generalized | Increased antioxidant defence; Reduced mitochondrial redox activity | [119] | |
Antioxidant | Cannabidiol | Inhibits GRP55; Desensitizes receptor potential vanilloid type-1; Inhibits adenosine uptake, | Drug-resistant | Decreased ROS production; Increased antioxidant defences | [120,121,122] |
Naringenin | Free radical scavenger | Pilocarpine-induced | Increased glutathione and antioxidant enzymes levels | [123] | |
Coenzyme Q10 | Increases the levels of TCA and antioxidant enzymes | Pilocarpine-induced | Increased SOD and GSH levels, reduced lipid peroxidation | [124] | |
N-acetylcysteine | Reduces glutathione precursor | Pentylenetetrazole-induced | Attenuated the impairment in glutathione homeostasis | [125] | |
Curcumin | Free radical scavenger and metal chelator | Pentylenetetrazole-induced | Increased superoxide dismutase levels Reduced the expression of inflammatory cytokines and chemokines Reduced GFAP and IBA-1 markers |
[126] | |
Vitamin E | Peroxyl radical scavenger | Refractory | Increased antioxidant capacity. Increased catalase and glutathione levels | [127] | |
Sulforaphane | Activates NRF2/ARE pathway | Status epilepticus | Decreased malondialdehyde levels and increased glutathione levels | [128] | |
Anti-inflammatory | Anakinra | Antagonist of IL-1 receptor | Febrile infection- related epilepsy syndrome and Intractable epilepsy | Reduced IL-1 driven systemic autoinflammation | [129,130,131,132] |
Anakinra + Canakinumab | Antagonist of IL-1 receptor; Monoclonal antibody against the IL-1 receptor | Generalized | |||
Tocilizumab | Anti-IL-6 monoclonal antibody | Status epilepticus, acute epilepsy | Reduced IL-6 levels | [133,134] | |
Minocycline | Inhibitor of microglia activation | Drug-resistant | Supressed IL-1β release from microglia | [135] | |
Adalimumab | Anti-TNF monoclonal antibody | Partial and focal motor seizures | Reduced TNF-α levels | [136] | |
Aspirin | Cyclooxygenase inhibitor | Focal-onset | Not reported | [137,138] | |
VX09-765-401 | IL-1β inhibitor | Partial seizures | Not reported | [139] |